• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

钠-葡萄糖协同转运蛋白2抑制剂诱导的正常血糖性糖尿病酮症酸中毒：可能机制及影响因素

Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors.

作者信息

Ogawa Wataru, Sakaguchi Kazuhiko

机构信息

Division of Diabetes and Endocrinology Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.

出版信息

J Diabetes Investig. 2016 Mar;7(2):135-8. doi: 10.1111/jdi.12401. Epub 2015 Sep 6.

DOI:10.1111/jdi.12401
PMID:27042263
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4773669/
Abstract

It is possible that SGLT2 inhibitors trigger euglycemic diabetic ketoacidosis in some patients. Possible mechanism of euglycemic DKA induced by SGLT2 inhibitors is illustrated.

摘要

钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂有可能在某些患者中引发正常血糖性糖尿病酮症酸中毒。文中阐述了SGLT2抑制剂诱发正常血糖性糖尿病酮症酸中毒的可能机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b318/4773669/caa2c30bb8ee/JDI-7-135-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b318/4773669/caa2c30bb8ee/JDI-7-135-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b318/4773669/caa2c30bb8ee/JDI-7-135-g001.jpg

相似文献

1
Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors.钠-葡萄糖协同转运蛋白2抑制剂诱导的正常血糖性糖尿病酮症酸中毒：可能机制及影响因素
J Diabetes Investig. 2016 Mar;7(2):135-8. doi: 10.1111/jdi.12401. Epub 2015 Sep 6.
2
SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：对原发性文献中糖尿病酮症酸中毒及相关危险因素的系统评价
Pharmacotherapy. 2017 Feb;37(2):187-194. doi: 10.1002/phar.1881. Epub 2017 Jan 16.
3
SGLT2 Inhibitors and Ketoacidosis: Cause for Concern?钠-葡萄糖协同转运蛋白2抑制剂与酮症酸中毒：值得关注的原因？
Metab Syndr Relat Disord. 2016 Feb;14(1):1-2. doi: 10.1089/met.2015.29002.aba. Epub 2015 Nov 10.
4
Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin.使用卡格列净治疗伴有持续性利尿的正常血糖性糖尿病酮症酸中毒
Intern Med. 2017;56(2):187-190. doi: 10.2169/internalmedicine.56.7501. Epub 2017 Jan 15.
5
Diabetic ketoacidosis precipitated by therapy with antidiabetic agents SGLT2 inhibitors: two cases.抗糖尿病药物SGLT2抑制剂治疗引发的糖尿病酮症酸中毒：两例病例
Crit Care Resusc. 2015 Dec;17(4):280-2.
6
Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives.SGLT2抑制剂相关的酮症及糖尿病酮症酸中毒：基本机制与治疗前景
Diabetes Metab Res Rev. 2017 Jul;33(5). doi: 10.1002/dmrr.2886. Epub 2017 Feb 23.
7
Insights Into the Recognition and Management of SGLT2-Inhibitor-Associated Ketoacidosis: It's Not Just Euglycemic Diabetic Ketoacidosis.对SGLT2抑制剂相关酮症酸中毒的认识与管理：不仅仅是正常血糖性糖尿病酮症酸中毒
Can J Diabetes. 2017 Oct;41(5):499-503. doi: 10.1016/j.jcjd.2017.05.004. Epub 2017 Aug 7.
8
Euglycemic diabetic ketoacidosis with canagliflozin: Not-so-sweet but avoidable complication of sodium-glucose cotransporter-2 inhibitor use.卡格列净所致的正常血糖性糖尿病酮症酸中毒：钠-葡萄糖协同转运蛋白2抑制剂使用中并非那么甜蜜但可避免的并发症
Can Fam Physician. 2016 Sep;62(9):725-8.
9
Letter to the Editor: Comment on "SGLT2 inhibitors may predispose to ketoacidosis" by Taylor S.I., et al.致编辑的信：对泰勒·S.I.等人所著《SGLT2抑制剂可能易引发酮症酸中毒》的评论
J Clin Endocrinol Metab. 2016 Feb;101(2):L27-8. doi: 10.1210/jc.2015-4236.
10
Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney.糖尿病酮症酸中毒、钠-葡萄糖协同转运蛋白2抑制剂与肾脏
J Diabetes Complications. 2016 Aug;30(6):1162-6. doi: 10.1016/j.jdiacomp.2016.05.008. Epub 2016 May 10.

引用本文的文献

1
Euglycemic diabetic ketoacidosis associated with etogliflozin in post-pancreatitis diabetes: A case report.胰源性糖尿病患者中恩格列净所致正常血糖性糖尿病酮症酸中毒：一例报告
World J Clin Cases. 2025 Sep 26;13(27):108550. doi: 10.12998/wjcc.v13.i27.108550.
2
Factors and preventive strategies for perioperative euglycemic diabetic ketoacidosis in patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors: a retrospective study.2型糖尿病患者接受钠-葡萄糖协同转运蛋白2抑制剂治疗时围手术期正常血糖性糖尿病酮症酸中毒的相关因素及预防策略：一项回顾性研究
J Pharm Health Care Sci. 2025 Aug 25;11(1):79. doi: 10.1186/s40780-025-00487-6.
3

本文引用的文献

1
Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet.一名低碳水化合物饮食的糖尿病患者使用钠-葡萄糖协同转运蛋白2抑制剂后发生酮症酸中毒的病例。
J Diabetes Investig. 2015 Sep;6(5):587-90. doi: 10.1111/jdi.12330. Epub 2015 Feb 20.
2
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.正常血糖性糖尿病酮症酸中毒：钠-葡萄糖协同转运蛋白2抑制剂治疗的一种潜在并发症。
Diabetes Care. 2015 Sep;38(9):1687-93. doi: 10.2337/dc15-0843. Epub 2015 Jun 15.
3
SGLT-2 inhibition and glucagon: Cause for alarm?
Euglycemic diabetic ketoacidosis associated with a sodium-glucose co transporter 2 inhibitor use in a trauma patient: a case report.
与钠-葡萄糖协同转运蛋白2抑制剂使用相关的正常血糖性糖尿病酮症酸中毒在一名创伤患者中的病例报告
Int J Emerg Med. 2025 Aug 13;18(1):152. doi: 10.1186/s12245-025-00963-8.
4
Clinical features and outcomes of diabetic ketoacidosis in patients using SGLT2 inhibitors: A systematic review and meta-analysis.使用钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂的患者糖尿病酮症酸中毒的临床特征及结局：一项系统评价和荟萃分析
Diabetes Obes Metab. 2025 Oct;27(10):5805-5811. doi: 10.1111/dom.16635. Epub 2025 Jul 21.
5
The state of the art in medical therapies for pediatric heart failure.小儿心力衰竭的医学治疗现状。
JHLT Open. 2025 May 29;9:100292. doi: 10.1016/j.jhlto.2025.100292. eCollection 2025 Aug.
6
[Not Available].[无可用内容]
CMAJ. 2025 Jul 13;197(25):E731-E734. doi: 10.1503/cmaj.241400-f.
7
2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association.《2025年韩国糖尿病管理临床实践指南：韩国糖尿病协会的建议》
Diabetes Metab J. 2025 Jul;49(4):582-783. doi: 10.4093/dmj.2025.0469. Epub 2025 Jul 1.
8
Renal and Safety Outcomes of SGLT2 Inhibitors in Patients with Type 2 Diabetes: A Nationwide Observational Cohort Study.钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者肾脏及安全性的影响：一项全国性观察性队列研究
J Clin Med. 2025 May 12;14(10):3349. doi: 10.3390/jcm14103349.
9
Euglycemic Diabetic Ketoacidosis and Thyroid Storm Occurring During Dapagliflozin Treatment.达格列净治疗期间发生的正常血糖性糖尿病酮症酸中毒和甲状腺风暴
JCEM Case Rep. 2025 May 21;3(7):luaf086. doi: 10.1210/jcemcr/luaf086. eCollection 2025 Jul.
10
Diabetic ketoacidosis induced by a sodium-glucose cotransporter-2 inhibitor in a 28-year-old man without known diabetes.一名28岁无糖尿病史男性因钠-葡萄糖协同转运蛋白2抑制剂诱发糖尿病酮症酸中毒。
CMAJ. 2025 May 4;197(17):E478-E481. doi: 10.1503/cmaj.241400.
钠-葡萄糖协同转运蛋白2（SGLT-2）抑制与胰高血糖素：需要警惕吗？
Trends Endocrinol Metab. 2015 Jul;26(7):337-8. doi: 10.1016/j.tem.2015.05.011. Epub 2015 Jun 6.
4
SGLT inhibition and euglycaemic diabetic ketoacidosis.钠-葡萄糖协同转运蛋白抑制与正常血糖性糖尿病酮症酸中毒
Lancet Diabetes Endocrinol. 2015 Jul;3(7):503-4. doi: 10.1016/S2213-8587(15)00204-1. Epub 2015 May 27.
5
Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians.体成分是导致日本人和高加索人 2 型糖尿病发病机制差异的主要决定因素。
Diabetes Care. 2014;37(3):796-804. doi: 10.2337/dc13-0598. Epub 2013 Oct 15.